Biomedical papers - Ahead of Print

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | 10.5507/bp.2017.049

Clinicopathological correlation of tumor-associated macrophages in Ewing sarcoma

Marek Handla, Marketa Hermanovab, Sylva Hotarkovab, Jiri Jarkovskyc, Peter Mudryd, Tetiana Shatokhinab, Marcela Veselab, Jaroslav Sterbad, Iva Zambob
a Faculty of Medicine, Masaryk University, Brno, Czech Republic
b 1st Department of Pathological Anatomy, Faculty of Medicine, Masaryk University, Brno and St. Anne's University Hospital, Brno, Czech Republic
c Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
d Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Aims: Tumor-associated macrophages (TAMs) are known markers playing complex roles in tumorigenesis. However, the function of TAMs in a variety of malignancies is not yet fully understood. The aim of this pilot study was to quantify the density of TAMs in Ewing sarcoma and to determine the correlation between TAMs and clinicopathological parameters.

Methods: Using immunohistochemistry, the expressions of CD68 and CD163 were examined in 24 tissue samples of Ewing sarcoma of bone. The density of CD68 and CD163-positive TAMs was analyzed quantitatively and semi-quantitatively and statistically correlated with clinical parameters.

Results: CD163-positive TAMs outnumbered CD68-positive cells (median of 130 vs 96, respectively). No statistically significant relatio nship was found between density of CD68-positive cells, clinical parameters or prognosis. However, high levels of CD163-positive TAMs were associated with localized disease (P=0.008). In cases with a higher density of CD163-positive cells, a trend toward longer survival was revealed (P=0.063).

Conclusion: This is the first study that has quantified CD163 expression in TAMs in Ewing sarcoma and showed its possible prognostic value. CD163 was confirmed to be a more specific marker of macrophages than CD68. CD163 is not an exclusive hallmark of M2 macrophages.

Keywords: tumor associated macrophages, Ewing sarcoma, immunohistochemistry, CD68, CD163, prognosis

Received: August 3, 2017; Accepted: October 26, 2017; Prepublished online: November 21, 2017


References

  1. Alava E, Lessnick SL, Sorensen PH. Ewing sarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone, 4th ed, Lyon: IARC; 2013. p. 306-339.
  2. Duchman KR, Gao Z, Miller BJ. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiology 2015;39:189-95. doi: 10.1016/j.canep.2015.05.001 Go to original source...
  3. Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voute PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 
975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study group. J Clin Oncol 2000;18(17):3108-14. Go to original source...
  4. Esiashvili N, Goodman M, Marcus RB. Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades: Surveillance Epidemiology and End Results Data. J Pediatr Hematol Oncol 2008;30(6):425-30. doi:10.1097/MPH.0b013e31816e22f3 Go to original source...
  5. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Landanyi M. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse, J Clin Oncol 2005;23(3):548-58. Go to original source...
  6. Futamura N, Nishida Y, Urakawa H, Kozawa E, Ikuta K, Hamada S, Ishiguro N. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma. Tumour Biol 2014;35(6):5159-65. doi: 10.1007/s13277-014-1668-8 Go to original source...
  7. Pietras K, Östman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 2010;316(8):1324-31. doi:10.1016/j.yexcr.2010.02.045 Go to original source...
  8. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141(1):39-51. doi:10.1016/j.cell.2010.03.014 Go to original source...
  9. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010;24(3):241-55. doi:10.1101/gad.1874010 Go to original source...
  10. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the Tumor Microenvironment. Cell 2010;141(1):52-67. doi:10.1016/j.cell.2010.03.015 Go to original source...
  11. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66(2):605-12. Go to original source...
  12. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23(3):277-86. doi:10.1016/j.ccr.2013.02.013 Go to original source...
  13. Shabo I, Olsson H, Sun XF, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer 2009;125:1826-31. doi: 10.1002/ijc.24506 Go to original source...
  14. Kawamura K, Konohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009;59(5):300-5. doi: 10.1111/j.1440-1827.2009.02369.x Go to original source...
  15. Fujiwara T, Fukushi J, Yamamoto S, Matsumoto Y, Setsu N, Oda Y, Yamada H, Okada S, Watari K, Ono M, Kuwano M, Kamura S, Iida K, Okada Y, Koga M, Iwamoto Y. Macrophage Infiltration Predicts a Poor Prognosis for Human Ewing Sarcoma. Am J Pathol 2011;179(3):1157-70. doi:10.1016/j.ajpath.2011.05.034 Go to original source...
  16. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S. Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer. J Surg Res 2011;167(2):e211-e219. doi:10.1016/j.jss.2009.05.026 Go to original source...
  17. Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010;10:112. doi: 10.1186/1471-2407-10-112 Go to original source...
  18. Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 2011;17(8):2110-19. doi: 10.1158/1078-0432.CCR-10-2047 Go to original source...
  19. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012;7(10):e47045. doi: 10.1371/journal.pone.0047045 Go to original source...
  20. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009;33(1):118-26. doi:10.1183/09031936.00065708 Go to original source...
  21. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PloS One 2012;17(12):e50946. doi:10.1371/journal.pone.0050946 Go to original source...
  22. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23(11):549-55. doi: 10.1016/S1471-4906(02)02302-5 Go to original source...
  23. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22(2):231-7. doi:10.1016/j.coi.2010.01.009 Go to original source...
  24. Heusinkveld M, Van Der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011;9:216. doi: 10.1186/1479-5876-9-216 Go to original source...
  25. Gordon S, Martinez FO. Alternative Activation of Macrophages: Mechanism and Functions. Immunity 2010;32(5):593-604. doi:10.1016/j.immuni.2010.05.007 Go to original source...
  26. Mosser DM and Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8(12):958-69. Go to original source...
  27. Schouppe E, De Baetselier P, Van Ginderachter JA, Sarukhan A. Instruction of myeloid cells by the tumor microenvironment: open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Oncoimmunology 2012;1(2):1135-45. doi:10.4161/onci.21566 Go to original source...
  28. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. The Lancet 2001;357(9255):539-45. doi:10.1016/S0140-6736(00)04046-0 Go to original source...
  29. Hao NB, Mlü MH, Fan YH, Cao YL, Zhang ZR. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012;2012:948098. doi: 10.1155/2012/948098 Go to original source...
  30. Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 2012;4(4):376-89.
  31. Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, Sakashita N, Araki N, Takeya M. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006;54(7):763-71. doi:10.1369/jhc.5A6871.2006 Go to original source...
  32. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008;216(1):15-24. doi:10.1002/path.2370 Go to original source...
  33. Gloghini A, Rizzo A, Zanette I, Canal B, Rupolo G, Bassi P, Carbone A. KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas. Am J Clin Pathol 1995;103(4):425-31. Go to original source...
  34. Tsang WY, Chan JK. KP1 (CD68) staining of granular cell neoplasms: is KP1 a marker for lysosomes rather than the histiocytic lineage? Histopathology 1992;21(1):84-6. Go to original source...
  35. Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Müller A, Kastenberger M, Brockhoff G, Andreesen R, Kreutz M. Expression of CD68 in non-myeloid cell types. Scand J Immunol 2008;67(5):453-63. doi: 10.1111/j.1365-3083.2008.02091.x Go to original source...
  36. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkuman Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 2005;29(5):617-24. Go to original source...
  37. Barros MH, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PloS One 2013;8(11):e80908. doi:10.1371/journal.pone.0080908 Go to original source...
  38. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012;7:12. doi: 10.1186/1746-1596-7-12 Go to original source...
  39. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007;5:62. doi:10.1186/1479-5876-5-62 Go to original source...
  40. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, Spector M. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2011;23(3):736-42 doi:10.1093/annonc/mdr157 Go to original source...
  41. Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One 2013;8(3):e59771. doi: 10.1371/journal.pone.0059771 Go to original source...
  42. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, van de Rijn M. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008;14(5):1423-30. doi: 10.1158/1078-0432.CCR-07-1712 Go to original source...
  43. Van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, Hogendoorn PC, van der Burg SH, Gelderblom H, van Hall T.. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 2010;127(4):899-909. doi: 10.1002/ijc.25113 Go to original source...